Results 21 to 30 of about 3,769,586 (361)

Acknowledgement to Reviewers of Antibodies in 2019

Antibodies, 2020
The editorial team greatly appreciates the reviewers who have dedicated their considerable time andexpertise to the journal’s rigorous editorial process over the past 12 months[...]
Antibodies Editorial Office
doaj   +1 more source

Animal Models of IgE Anaphylaxis

Biology, 2023
Allergies and atopy have emerged as significant public health concerns, with a progressively increasing incidence over the last two decades. Anaphylaxis is the most severe form of allergic reactions, characterized by a rapid onset and potentially fatal ...
Aurélie Gouel-Chéron, Alice Dejoux, Emma Lamanna, Pierre Bruhns   +3 more
doaj   +1 more source

Isolation of a human SARS-CoV-2 neutralizing antibody from a synthetic phage library and its conversion to fluorescent biosensors

Scientific Reports, 2022
Since late 2019, the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resultant spread of COVID-19 have given rise to a worldwide health crisis that is posing great challenges to public health and clinical treatment, in ...
Haimei Li, Bo Zhu, Baowei Li, Limei Chen, Xuerao Ning, Hang Dong, Jingru Liang, Xueying Yang, Jinhua Dong, Hiroshi Ueda   +9 more
doaj   +1 more source

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Science, 2020
An antibody defense against COVID-19 One of the responses of the immune system to invading viruses is the production of antibodies. Some of these are neutralizing, meaning that they prevent the virus from being infectious, and can thus be used to treat ...
Yan Wu, Feiran Wang, Chenguang Shen, Weiyu Peng, Delin Li, Cheng Zhao, Z. Li, Shihua Li, Y. Bi, Yang Yang, Y. Gong, Haixia Xiao, Z. Fan, Shuguang Tan, Guizhen Wu, W. Tan, Xuancheng Lu, Changfa Fan, Qihui Wang, Yingxia Liu, Chen Zhang, J. Qi, G. Gao, F. Gao, Lei Liu   +24 more
semanticscholar   +1 more source

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Science, 2020
SARS-CoV-2 antibodies persist As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al.
A. Wajnberg, F. Amanat, A. Firpo, D. Altman, M. Bailey, M. Mansour, Meagan McMahon, Philip Meade, D. R. Mendu, K. Muellers, D. Stadlbauer, K. Stone, Shirin Strohmeier, V. Simon, J. Aberg, D. Reich, F. Krammer, C. Cordon-Cardo   +17 more
semanticscholar   +1 more source

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

Science, 2021
Description Community of antibodies against COVID-19 The severe acute respiratory syndrome coronavirus 2 spike protein is the basis of many vaccines and is a primary target of neutralizing antibodies after COVID-19 infection.
K. Hastie, Haoyang Li, Daniel H Bedinger, S. Schendel, S. Dennison, Kan Li, V. Rayaprolu, Xiaoying Yu, Colin J. Mann, M. Zandonatti, Ruben Diaz Avalos, D. Żyła, Tierra Buck, S. Hui, K. Shaffer, C. Hariharan, J. Yin, Eduardo Olmedillas, Adrian Enriquez, D. Parekh, Milite Abraha, Elizabeth Feeney, Gillian Q. Horn, Y. Aldon, Hanif Ali, Sanja Aracic, Ronald R Cobb, Ross S. Federman, Joseph M. Fernandez, J. Glanville, Robin Green, G. Grigoryan, Ana G. Lujan Hernandez, D. Ho, Kuan-Ying A. Huang, J. Ingraham, Weidong Jiang, P. Kellam, Cheolmin Kim, Minsoo Kim, Hyeong Mi Kim, Chao Kong, S. Krebs, F. Lan, Guojun Lang, Sooyoung Lee, Cheuk Lun Leung, Junli Liu, Yanan Lu, Anna J. MacCamy, A. McGuire, A. Palser, T. Rabbitts, Zahra Rikhtegaran Tehrani, Mohammad M. Sajadi, R. Sanders, A. Sato, L. Schweizer, Jimin Seo, Bingqing Shen, Jonne L. Snitselaar, L. Stamatatos, Yongcong Tan, M. Tomic, M. V. van Gils, S. Youssef, Jian Yu, Tom Z. Yuan, Qian Zhang, B. Peters, G. Tomaras, T. Germann, E. Saphire   +72 more
semanticscholar   +1 more source

The Antibody Society’s antibody validation webinar series [PDF]

mAbs, 2020
In the wake of the reproducibility crisis and numerous discussions on how commercially available antibodies as research tool contribute to it, The Antibody Society developed a series of 10 webinars to address the issues involved. The webinars were delivered by speakers with both academic and commercial backgrounds.
Andrew Bradbury, C. Glenn Begley, Alejandra Solache, Giovanna Roncador, Andrew D. Chalmers, Cecilia Williams, Cecilia Williams, Fridtjof Lund-Johansen, Travis Hardcastle, Andreas Plückthun, Michael J. Taussig, Jan L.A. Voskuil, Aldrin V. Gomes, Simon L. Goodman, James S. Trimmer, Anita Bandrowski   +15 more
openaire   +6 more sources

Expression cloning and production of Human Heavy Chain Only antibodies from murine transgenic plasma cells

Frontiers in Immunology, 2016
Several technologies have been developed to isolate human antibodies against different target antigens as a source of potential therapeutics, including hybridoma technology, phage and yeast display systems.
Dubravka Drabek, Rick Janssens, Ernie de Boer, Rik Rademaker, Johannes Kloess, John Skehel, Frank Grosveld, Frank Grosveld   +7 more
doaj   +1 more source

Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model

Frontiers in Oncology, 2022
DNA-encoded delivery and in vivo expression of antibody therapeutics presents an innovative alternative to conventional protein production and administration, including for cancer treatment.
Kevin Hollevoet, Kevin Hollevoet, Debby Thomas, Debby Thomas, Griet Compernolle, Griet Compernolle, Giles Vermeire, Elien De Smidt, Elien De Smidt, Stéphanie De Vleeschauwer, Trevor R. F. Smith, Paul D. Fisher, Maarten Dewilde, Maarten Dewilde, Nick Geukens, Paul Declerck, Paul Declerck   +16 more
doaj   +1 more source

Acknowledgement to Reviewers of Antibodies in 2016

Antibodies, 2017
The editors of Antibodies would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2016.[...]
Antibodies Editorial Office
doaj   +1 more source